source
- Alkermes reports Phase 3 success for Lumryz; Boehringer announces antibody partnershipAlkermes announced that its narcolepsy medication Lumryz, which received regulatory approval in 2023, achieved its primary efficacy endpoint in a Phase 3 trial. The study met the predefined criter…
- Pain drug research gains momentum a year after Vertex launch as new startups revive sodium channel targetsA year after Vertex introduced its breakthrough pain medication, the field of pain drug development is at a pivotal crossroads. Analysts note that renewed scientific focus and investor interest are…